Alector Reports First Quarter 2025 Financial Results and Provides Business Update
Alector, Inc. (ALEC)
Last alector, inc. earnings: 3/24 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer’s disease Continuing to pursue Alector Brain Carrier programs, including the company’s anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported first quarter 2025 financial results and recent portfolio and business updates. As of March 31, 2025, Alector’s cash, cash equivalents, and investments totaled $354.6 million. "With cash runway extending into the second half of 2027, Alector is advancing a portfolio of drug candidates
Show less
Read more
Impact Snapshot
Event Time:
ALEC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALEC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALEC alerts
High impacting Alector, Inc. news events
Weekly update
A roundup of the hottest topics
ALEC
News
- Alector Provides Executive Leadership Update [Yahoo! Finance]Yahoo! Finance
- Alector Provides Executive Leadership UpdateGlobeNewswire
- Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewswire
- Alector, Inc. (NASDAQ: ALEC) had its price target raised by analysts at HC Wainwright from $7.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Alector to Participate in Upcoming Healthcare ConferencesGlobeNewswire
ALEC
Earnings
- 2/26/25 - Beat
ALEC
Sec Filings
- 6/13/25 - Form 8-K
- 6/12/25 - Form 4
- 6/12/25 - Form 4
- ALEC's page on the SEC website